Impact Factor Current: 2.628
5 - Year: 3.148

Current Drug Targets - CNS & Neurological Disorders

(Continued as CNS & Neurological Disorders - Drug Targets)

ISSN (Print): 1568-007X
ISSN (Online): 1568-007X

Volume 4 , Issue 6 , 2005

Back Journal Home
Impact Factor
Web of Science Impact Factor

Current: 2.628
5 - Year: 3.148

Ranking & Category

  • 107th of 254 in Pharmacology & Pharmacy

Topic(s) Covered

2 Topic(s)

View
Covered Disease(s)

0 Disease(s)

Aims & Scope

CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

Abstracted/Indexed in


Dimensions, Science Citation Index Expanded, Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, Neuroscience Citation Index®, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts, PsycINFO, ProQuest, MediaFinder®-Standard Periodical Directory, Genamics JournalSeek, PubsHub and J-Gate.

Journal History

Current Drug Targets - CNS & Neurological Disorders was launched in 2002 and later renamed in 2006 as CNS & Neurological Disorders - Drug Targets.

Endorsement(s)

"This journal is the definitive source for the most meaningful and critical information available on CNS drug targets and progress both in industrial and academic based neurodegeneration research."

Rudolf E. Tanzi
Harvard Medical School, USA

Authors' Comments

I have nothing but positive comments for Bentham Science Publishers, as my experience has always been pleasant. I have always received prompt service from Bentham Science.

Dr. Celina S. Liu
Has contributed: Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction

© 2022 Bentham Science Publishers | Privacy Policy